| Literature DB >> 33708566 |
Xiaohui Zhang1, Huanwen Wu2, Zhe Wang1,2, Yidong Zhou1, Feng Mao1, Yan Lin1, Songjie Shen1, Zhiyong Liang2, Qiang Sun1.
Abstract
Tall cell carcinoma of the breast with reverse polarity (TCCRP), described firstly and also known as tall cell variant of papillary breast carcinoma (TCVPBC), is a rare type of breast cancer that mimics papillary thyroid carcinoma (PTC) histopathologically. As the incidence of this type of tumor is very low, awareness of it is crucial to ensuring that unnecessary clinical investigations are avoided. The present study examined a 45-year-old woman in China who was diagnosed with TCCRP. This paper outlines her demographic and clinicopathologic data, and her follow-up and immunohistochemical examination results. Furthermore, this study used the next-generation sequencing (NGS) technique to identify concurrent isocitrate dehydrogenase 2 (IDH2) and phosphatidylinositol 3-kinase catalytic alpha (PIK3CA) hotspot mutations. Notably, the novel results of the study showed that the IDH2 R120 (rather than the IDH2 R172) mutation may also be present in this disease. Additionally, a comprehensive literature review was conducted to elucidate some of the significant clinical and pathological features of this type of disease. This information may provide important insights that can be used in diagnosis and treatment. It is essential both for physicians and pathologists to recognize the existence of TCCRP, with its own specific clinical and pathological characteristics. Further research using molecular biology techniques should be conducted in the future to characterize this unique entity. 2021 Gland Surgery. All rights reserved.Entities:
Keywords: IDH2 mutation; Tall cell carcinoma with reverse polarity (TCCRP); breast cancer; case report; next-generation sequencing (NGS)
Year: 2021 PMID: 33708566 PMCID: PMC7944084 DOI: 10.21037/gs-20-695
Source DB: PubMed Journal: Gland Surg ISSN: 2227-684X